Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more
Traws Pharma Inc (TRAW) - Total Liabilities
Latest total liabilities as of September 2025: $7.90 Million USD
Based on the latest financial reports, Traws Pharma Inc (TRAW) has total liabilities worth $7.90 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Traws Pharma Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Traws Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Traws Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Traws Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Valor Resources Limited
PINK:VOYRF
|
USA | $2.27 Million |
|
PTL Enterprises Limited
NSE:PTL
|
India | ₹2.26 Billion |
|
Daura Gold Corp.
V:DGC
|
Canada | CA$819.15K |
|
MiMedia Holdings Inc.
V:MIM
|
Canada | CA$5.82 Million |
|
Innofactor Oyj
HE:IFA1V
|
Finland | €26.80 Million |
|
CN SINGYES
F:KG0A
|
Germany | €17.22 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Traws Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Traws Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Traws Pharma Inc (2011–2024)
The table below shows the annual total liabilities of Traws Pharma Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $56.59 Million | +371.17% |
| 2023-12-31 | $12.01 Million | +8.57% |
| 2022-12-31 | $11.06 Million | +18.22% |
| 2021-12-31 | $9.36 Million | -32.24% |
| 2020-12-31 | $13.81 Million | +14.14% |
| 2019-12-31 | $12.10 Million | -3.48% |
| 2018-12-31 | $12.54 Million | -20.86% |
| 2017-12-31 | $15.84 Million | -12.52% |
| 2016-12-31 | $18.11 Million | +43.64% |
| 2015-12-31 | $12.61 Million | -46.85% |
| 2014-12-31 | $23.71 Million | -2.22% |
| 2013-12-31 | $24.25 Million | -89.98% |
| 2012-12-31 | $242.16 Million | +69.48% |
| 2011-12-31 | $142.88 Million | -- |